Concepedia

Author

Shalabh Singhal

Bristol-Myers Squibb (United States)

Also Known As

S Singhal, S. Singhal, Shalabh Singhal, Singhal Shalabh, Sudhir Singhal

46

Publications

641

Citations

8

H-Index

11

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Amsterdam University Medical CentersOklahoma Medical Research FoundationMonash UniversityMonash Health
SS

About

Shalabh Singhal is an author at Bristol-Myers Squibb (United States) specializing in rheumatology, pharmacotherapy, and percutaneous coronary intervention.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

12

2

Pharmacology

1

1

12

3

Rheumatology

1

1

12

4

Inflammation

1

1

12

5

Inflammatory Arthritis

1

1

12

Shalabh Singhal

×

8

Publications

567

Citations

8

H-Index

YearCitations

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

Eric F. Morand, Marilyn C. Pike, Joan T. Merrill,

Arthritis & Rheumatology

2022

217

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Philip J. Mease, Atul Deodhar, Désirée van der Heijde,

Annals of the Rheumatic Diseases

2022

188

Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy

Deborah DeEugenio, Louis Kolman, Matthew DeCaro,

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

2007

92

LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

E. Morand, Margaret N. Pike, JT Merrill,

Annals of the Rheumatic Diseases

2022

19

Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin

Amanda M. Farr, Yonghua Jing, Stephen S. Johnston,

Hospital Practice

2015

14

POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Philip J. Mease, Atul Deodhar, D. van der Heijde,

Annals of the Rheumatic Diseases

2021

14

Prasugrel as a safe alternative for clopidogrel-associated arthritis.

Mehulkumar Kanadiya, Shalabh Singhal, Vipin B. Koshal

PubMed

2011

12

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects

Anjaneya Chimalakonda, Shalabh Singhal, Raymond B. Darbenzio,

Clinical Pharmacology in Drug Development

2022

11

Page 1